Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Accounts Payables: 2020-2025

Historic Accounts Payables for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $9.8 million.

  • Foghorn Therapeutics' Accounts Payables fell 12.45% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 12.45%. This contributed to the annual value of $8.5 million for FY2024, which is 6.34% down from last year.
  • As of Q3 2025, Foghorn Therapeutics' Accounts Payables stood at $9.8 million, which was up 14.69% from $8.6 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Accounts Payables high stood at $11.2 million for Q3 2024, and its period low was $2.9 million during Q1 2021.
  • For the 3-year period, Foghorn Therapeutics' Accounts Payables averaged around $8.4 million, with its median value being $8.6 million (2025).
  • In the last 5 years, Foghorn Therapeutics' Accounts Payables surged by 140.81% in 2022 and then decreased by 29.06% in 2024.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Accounts Payables stood at $9.6 million in 2021, then increased by 15.05% to $11.0 million in 2022, then declined by 17.21% to $9.1 million in 2023, then declined by 6.34% to $8.5 million in 2024, then declined by 12.45% to $9.8 million in 2025.
  • Its Accounts Payables was $9.8 million in Q3 2025, compared to $8.6 million in Q2 2025 and $6.5 million in Q1 2025.